Betta Pharmaceuticals Co

Company snapshot

Betta Pharmaceuticals Co., Ltd. (SZ300558), established in 2003 in Hangzhou, China, is one of the leading Chinese pharmaceutical companies dedicated to develop and commercialize innovative oncology products to meet high unmet medical needs. With over 1,300 employees in Hangzhou and Beijing, China, Betta’s development capabilities range from small molecule and biologics discovery, clinical developm

• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Betta Pharmaceuticals Co. Not investment advice.

• What is Betta Pharmaceuticals Co?

  Betta Pharmaceuticals Co is a pharma organization headquartered in CN. Primary therapeutic focus areas include Psoriasis, EGFR Positive Non-small Cell Lung Cancer. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA

• Is Betta Pharmaceuticals Co publicly traded?

  Betta Pharmaceuticals Co appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Betta Pharmaceuticals Co develop or market?

  We link 4 drug profile(s) where Betta Pharmaceuticals Co is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/betta-pharmaceuticals-co#company-drugs.

• What are the latest developments for Betta Pharmaceuticals Co?

  In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Betta Pharmaceuticals Co focus on?

  Betta Pharmaceuticals Co focuses on Psoriasis, EGFR Positive Non-small Cell Lung Cancer based on our analysis of their pipeline programs and drug development activities.